Trial Profile
KAND567 Versus Placebo in Subjects Hospitalized with COVID-19. A Phase II, Randomized, 2-Arm Parallel-Group, Double-blind Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs KAND-567 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kancera
- 19 Nov 2021 Top-line results presented in a Kancera media release.
- 25 Aug 2021 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 16 Jun 2021 According to a Kancera media release, the study results are expected to be presented during the fourth quarter of 2021.